Preclinical development of a novel CD47 nanobody with less toxicity and enhanced anti-cancer therapeutic potential

Overview of attention for article published in Journal of Nanobiotechnology, January 2020

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (72nd percentile)
High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

twitter: 3 X users

patent: 2 patents

Citations

dimensions_citation: 70 Dimensions

Readers on

mendeley: 61 Mendeley

Summary X Patents Dimensions citations

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 6,073 followers.

Preclinical development of a novel CD47 nanobody with less toxicity and enhanced anti-cancer therapeutic potential. #lymphoma #lymsm https://t.co/O32OziRPWL

11 Oct 2020

Reply Repost Favourite

Our #ReadOfTheWeek by a team from #Shanghai looked at characterizing a #nanobody fusion #protein with low affinity for RBCs as an alternative to #antibody targeting of #CD47 overexpression in tumour growth. Read more https://t.co/n95SADIzJZ #Nanobodies #I

24 Feb 2020

Reply Repost Favourite

J Nanobiotechnology Preclinical development of a novel CD47 nanobody with less toxicity and enhanced anti-cancer therapeutic potential: CD47, the integrin-related protein, plays an important role in immune resistance and… https://t.co/kfDzQiaBwP #Research

13 Jan 2020

Reply Repost Favourite